// App-Quantinova.ai

5688 : IND-enabling characterization of ONC206 as the next bitopic antagonist for oncology

Researchers

Presenter

  • Varun Vijay Prabhu

Principal Investigators

  • Caroline A. Cuoco

  • Abed R. Kawakibi

  • Jinkyu Jung

  • Neel Madhukar

  • Matthew J. Garnett

  • Ultan McDermott

  • Cyril H. Benes

  • Robert Wechsler-Reya

  • Lakshmi Anantharaman

  • Neil Charter

  • Joseph B. Rucker

  • Benjamin J. Doranz

  • Joel Basken

  • Olivier Elemento

  • R. Benjamin Free

  • David R. Sibley

  • Martin Stogniew

  • Wolfgang Oster

  • Mark R. Gilbert

  • Sharon DeMorrow

Medical Centers

  • Oncoceutics, Philadelphia, PA

  • NHLBI/NIH, Bethesda, MD.

  • CCR, NIH, Bethesda, MD

  • Weill Cornell Medical College, New York, NY

  • Wellcome Trust Sanger Institute, Cambridge, United Kingdom

  • Massachusetts General Hospital, Boston, MA

  • Sanford Burnham Prebys Medical Discovery Institute, Heidelberg, CA

  • Eurofins DiscoverX, Fremont, CA, USA

  • Integral Molecular, Philadelphia, PA.

  • Arpeggio Biosciences, Boulder, CO

  • Texas A&M College of Medicine, Bryan, TX

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Advanced biliary tract carcinoma

  • Glioblastoma

  • Solid malignancies

  • Gliomas

Biomarkers

  • Cyclic adenosine monophosphate

  • Cerebrospinal fluid

Drug/Treatment

  • Arrestin

  • Dopamine hydrochloride

  • TIC 10

Outcome

  • N/A

Study Design

  • First-In-Human

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved